PROMISING DIRECTIONS FOR PATHOGENIC TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA
Abstract
Today, diabetic retinopathy (DR) and diabetic macular edema (DME) are an urgent problem because of decrease in the quality of life and disability of patients with diabetes mellitus (DM). That is why an in-depth study of the mechanisms of development of these complications, search for new remedies and discussion of effective prescribing schemes are being conducted all over the world.This review presents modern pharmacotherapy, as well as the latest developments in new treatment methods aimed at the pathogenesis of DR and DME.
About the Authors
R. R. Ibragimova
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России
Russian Federation
Russian Federation
T. R. Mukhamadeev
ФГБОУ ВО «Башкирский государственный медицинский университет» Минздрава России; Центр лазерного восстановления зрения «OPTIMED»
Russian Federation
Russian Federation
References
1. Азнабаев Б.М. Оптическая когерентная томография+ангиография глаза/ Б.М. Азнабаев, Т.Р. Мухамадеев, Т.И. Дибаев - М.: Август Борг, 2019. - 352 с.: ил
2. Кирилюк, М.Л. Медикаментозное лечение и профилактика диабетической ретинопатии при сахарном диабете типа 1: обзор литературы и клинических исследований [Электронный ресурс] / М. Л. Кирилюк// МЭЖ. - 2012 - №5 (45). URL: https://cyberleninka.ru/article/n/medikamentoznoe-lechenie-i-profilaktika-diabeticheskoy-retinopatii-pri-saharnom-diabete-tipa-1-obzor-literatury-i-klinicheskih (дата обращения: 29.01.2020)
3. Ангиогенез при пролиферативной диабетической ретинопатии: перспективы антиvegf-терапии (обзор литературы)/ Коненков В.И. [и др.] // Офтальмохирургия. - 2013. - №4. - С. 111-115
4. Шадричев, Ф.Е. Антиангиогенная терапия при диабетическом макулярном отёке / Ф.Е Шадричев, Н.Н. Григорьева, Е.С. Рождественская // Офтальмологические ведомости. - 2018. - Т. 11. - №4. - С. 51-66
5. The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches/ Abdulaal M. [et al.] // Seminars in ophthalmology. - Taylor & Francis, 2016. - Т. 31. - №1-2. - С. 19-24
6. Bolinger M.T. Moving past anti-VEGF: novel therapies for treating diabetic retinopathy/ M.T. Bolinger, D.A. Antonetti // International journal of molecular sciences. - 2016. - Т. 17. - №9. - С. 1498-1505
7. Cheung N. Ocular anti-VEGF therapy for diabetic retinopathy: overview of clinical efficacy and evolving applications / N. Cheung, I.Y. Wong, T.Y. Wong // Diabetes care. - 2014. - Т. 37. - №4. - С. 900-905
8. Das A. Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon? / A. Das, P.G. McGuire, F. Monickaraj // Indian journal of ophthalmology. - 2016. - Т. 64. - №1. - С. 4
9. Dedania V.S. Novel pharmacotherapies in diabetic retinopathy / V.S. Dedania, S. J. Bakri // Middle East African journal of ophthalmology. - 2015. - Т. 22. - №2. - С. 164
10. Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema // New England Journal of Medicine. - 2015. - Т. 372. - №13. - С. 1193-1203
11. Low-dose minocycline mediated neuroprotection on retinal ischemia-reperfusion injury of mice / Huang R. [et al.] //Molecular vision. - 2018. - Т. 24. - С. 367
12. Marashi A. Using anti-vegf in diabetic retinopathy / A. Marashi //Adv Ophthalmol Vis Syst. - 2016. - Т. 4. - №4. - С. 00116
13. Miller K. Diabetic macular edema: Current understanding, pharmacologic treatment options, and developing therapies / K. Miller, J.A. Fortun // The Asia-Pacific Journal of Ophthalmology. - 2018. - Т. 7. - №1. - С. 28-35
14. Novel drugs and their targets in the potential treatment of diabetic retinopathy / Nawaz M.I. [et al.] // Medical science monitor: international medical journal of experimental and clinical research. - 2013. - Т. 19. - С. 300
15. Rangasamy S. Diabetic retinopathy and inflammation: novel therapeutic targets / S. Rangasamy, P.G. McGuire, A. Das // Middle East African journal of ophthalmology. - 2012. - Т. 19. - №1. - С. 52
16. Mechanistic insights into pathological changes in the diabetic retina: implications for targeting diabetic retinopathy / Roy S. [et al.] //The American journal of pathology. - 2017. - Т. 187. - №1. - С. 9-19
17. Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets / Safi S.Z. [et al.] //BioMed research international. - 2014. - Т. 2014
18. Simo R. Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy / R. Simo, C. Hernandez // Diabetologia. - 2008. - Т. 51. - №9. - С. 1574
19. Novel therapeutic targets in diabetic macular edema: beyond VEGF / Urias E.A. [et al.] // Vision research. - 2017. - Т. 139. - С. 221227
20. Diabetic retinopathy: a complex pathophysiology requiring novel therapeutic strategies / Whitehead M. [et al.] // Expert opinion on biological therapy. - 2018. - Т. 18. - №12. - С. 1257-1270
21. Yee K.H. Anti-vascular endothelial growth factor therapy in diabetic macular oedema: is it effective? / K.H. Yee, S. Sanjay // Diabetes. - 2017
22. Zhao Y. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy / Y. Zhao, R.P. Singh // Drugs in context. - 2018. - Т. 7
Review
For citations:
Ibragimova R.R., Mukhamadeev T.R. PROMISING DIRECTIONS FOR PATHOGENIC TREATMENT OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA. Bashkortostan Medical Journal. 2020;15(4):108-112. (In Russ.)
Views:
49
Email this article 
